Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zoster Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Partnership
GSK and Zhifei Announce Exclusive Strategic Vaccine Partnership in China
Details : Under the partnership, Zhifei will co-promote GSK’s shingles vaccine, Shingrix (recombinant zoster vaccine or RZV), a non-live, recombinant subunit vaccine in China for an initial three-year period.
Product Name : Shingrix
Product Type : Vaccine
Upfront Cash : Undisclosed
October 09, 2023
Lead Product(s) : Zoster Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : $14,800.0 million
Deal Type : Collaboration
MSD and Zhifei Renew Collaboration on Vaccines
Details : Under the collaboration, Zhifei will continue to purchase five vaccine products including, 4-valent and 9-valent HPV vaccine, Gardasil (recombinant human papillomavirus quadrivalent vaccine), pentavalent rotavirus vaccine and other agreed products from M...
Product Name : Gardasil
Product Type : Vaccine
Upfront Cash : Undisclosed
January 21, 2023
Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : $14,800.0 million
Deal Type : Collaboration
Reset All
